Cargando…

Adverse events during short- and long-term exposure to low-dose weekly methotrexate for rheumatic diseases

Detalles Bibliográficos
Autores principales:	Garton, Mark, Teoh, Yee-Ping, Watson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Letter to the Editor (Other)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147515/ https://www.ncbi.nlm.nih.gov/pubmed/37122806 http://dx.doi.org/10.1093/rap/rkad038

Ejemplares similares

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Methotrexate in Rheumatic Disease
por: Hughes, Graham R V
Publicado: (1994)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

In vitro inhibition of HUVECs by low dose methotrexate – insights into oral adverse events
por: Annussek, Tobias, et al.
Publicado: (2014)

Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease
por: Muanda, Flory T., et al.
Publicado: (2023)

Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus‐treated transplant recipients?
por: Robertsen, Ida, et al.
Publicado: (2019)

Procedural pain and patient-reported side effects with weekly injections of subcutaneous Methotrexate in children with rheumatic disorders
por: Bechard, Melanie Anne, et al.
Publicado: (2014)

Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases
por: Mori, Shunsuke, et al.
Publicado: (2016)

Palliative low dose fortnightly methotrexate in oral cancer
por: Tin, Sim Sai, et al.
Publicado: (2015)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Hypercalcemia with methotrexate pneumonitis: A rare, important and intriguing adverse event
por: Samant, R, et al.
Publicado: (2022)

Long‐term outcomes of combined intravitreal methotrexate and systemic high‐dose methotrexate therapy in vitreoretinal lymphoma
por: Cheng, Chieh‐Lung, et al.
Publicado: (2023)

Effect of low dose methotrexate as an add-on therapy in patients with palindromic rheumatism unresponsive to hydroxychloroquine: An observational study
por: Padhan, Prasanta, et al.
Publicado: (2021)

Autoimmune hepatitis as an adverse effect of long-term methotrexate therapy
por: Ksouda, Kamilia, et al.
Publicado: (2014)

LD(50) dose fixation of nanohybrid-layered double hydroxide-methotrexate
por: Mishra, Akhilesh, et al.
Publicado: (2022)

Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study
por: Dubey, Lily, et al.
Publicado: (2016)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose
por: Chen, Po-Yu, et al.
Publicado: (2022)

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

Methotrexate-Induced Mucositis: A Consequence of Medication Error in a Rheumatoid Arthritis Patient
por: Shrestha, Rujen, et al.
Publicado: (2023)

Adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity
por: van der Hul, René L., et al.
Publicado: (2003)

The working week: spoken business English with a lexical approach
por: Watson-Delestree, et al.
Publicado: (2001)

Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events?
por: Durfey, Nicole, et al.
Publicado: (2017)

The effect of repeated methotrexate injections on the quality of life of children with rheumatic diseases
por: Jacobse, Justin, et al.
Publicado: (2018)

Biological and Methotrexate Survival after Pregnancy in Patients With a Rheumatic Disease
por: Tahmasian, Helena, et al.
Publicado: (2022)

A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring
por: Liu, Xin, et al.
Publicado: (2020)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
por: Bobircă, Anca, et al.
Publicado: (2021)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Revisional Gastric Bypass Is Inferior to Primary Gastric Bypass in Terms of Short- and Long-term Outcomes—Systematic Review and Meta-Analysis
por: Pędziwiatr, Michał, et al.
Publicado: (2018)

Clinical decision-making in remote rheumatology consultations: a service evaluation of new patient and inflammatory rheumatic disease follow-up appointments
por: Tarar, Ahmed B, et al.
Publicado: (2021)

Counselling services embedded within rheumatology clinics could help bridge the gap in mental health care provision for adults with rheumatic diseases
por: Hayward, Georgia, et al.
Publicado: (2022)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Severe hypoglycemia with trastuzumab: An unseen adverse event
por: Amrith, B. P., et al.
Publicado: (2019)

Oral pulsed high-dose dexamethasone therapy for rheumatic diseases: An alternative safe and effective scheme
por: de Carvalho, Jozélio Freire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7n5aujbu487jebkr4mvv0vo7f9